Arch Biopartners Inc.
ARCH.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 114.30K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 114.30K | -- |
| Cost of Revenue | 116.10K | 360.20K | -100.30K | 82.90K | 90.40K |
| Gross Profit | -116.10K | -360.20K | 100.30K | 31.30K | -90.40K |
| SG&A Expenses | 177.40K | 687.50K | 228.00K | 174.30K | 263.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 293.60K | 1.05M | 127.70K | 257.30K | 353.50K |
| Operating Income | -293.60K | -1.05M | -127.70K | -143.00K | -353.50K |
| Income Before Tax | -374.70K | -1.12M | -195.90K | -175.20K | -384.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -374.70K | -1.12M | -195.90K | -175.20K | -384.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -374.70K | -1.12M | -195.90K | -175.20K | -384.30K |
| EBIT | -293.60K | -1.05M | -127.70K | -143.00K | -353.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.02 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 66.94M | 66.11M | 65.51M | 66.11M | 65.47M |
| Average Diluted Shares Outstanding | 66.94M | 66.11M | 65.51M | 66.11M | 65.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |